<DOC>
	<DOCNO>NCT00897533</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment erlotinib . PURPOSE : This laboratory study develop model predict progression-free survival erlotinib patient non-small cell lung cancer .</brief_summary>
	<brief_title>Development Model Predict Progression-Free Survival After Erlotinib Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess mesenchymal epithelial marker tissue patient non-small cell lung cancer treat erlotinib hydrochloride clinical trial ECOG-E3503 . - Determine loss epithelial marker ( E-cadherin ) gain mesenchymal marker ( vimentin/cytokeratin co-expression ) patient . - Assess whether mesenchymal epithelial marker predictive progression-free survival ( PFS ) patient . - Identify single nucleotide polymorphism profile via whole genome mapping know biomarkers predict PFS patient . OUTLINE : Tissue sample analyze whole genome mapping single nucleotide polymorphism ( SNP ) rate signal detection rate quantitative immunohistochemistry mesenchymal ( vimentin/cytokeratin ) epithelial ( E-cadherin ) marker transition . After biomarker identification gene map complete , model predict progression-free survival patient develop . PROJECTED ACCRUAL : A total 137 sample accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonsmall cell lung cancer , include follow subtypes : Adenocarcinoma Squamous cell carcinoma Bronchoalveolar carcinoma Carcinoid Stage IIIB IV recurrent disease Must receive treatment erlotinib hydrochloride clinical trial ECOGE3503 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>